Connecting academia and industry for innovative drug repurposing in rare diseases: it is worth a try

Abstract

There are different approaches to drug repurposing (DR) depending on the status of the repurposable drug/molecule (approved, investigational, withdrawn, shelved), the context, and the stakeholders involved. The purpose of this perspective paper is to highlight the complexity of academia-industry collaborations in DR for rare diseases and go beyond stereotypes to consider realistic and mutually reinforcing cooperation among various stakeholders, including not only academia and industry but also regulators, legal experts, and payers, leading to benefits for patients with unmet medical needs. Key questions are addressed through the presentation of select DR case studies. Some ongoing and promising European and international initiatives are introduced and recommendations are proposed.

Keywords

Drug repurposing / academia-industry collaboration / rare diseases / sildenafil / alpelisib / propranolol

References

[1] Murteira S,Karray S.Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature.J Mark Access Health Policy2013;1:21131 PMCID:PMC4865745

[2] Mucke HAM.COVID-19 and the drug repurposing tsunami.Assay Drug Dev Technol2020;18:211-4

[3] Galindez G,Rose TD.Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies.Nat Comput Sci2021;1:33-41

[4] European Medicines Agency. Orphan medicinal product designation 2000-2020. Available from: https://www.ema.europa.eu/en/documents/other/orphan-medicines-figures-2000-2020_en.pdf [Last accessed on 7 Apr 2023]

[5] European Medicines Agency. Support for development of orphan medicines. Available from: https://www.ema.europa.eu/en/documents/report/report-workshop-support-orphan-medicines-development_en.pdf [Last accessed on 7 Apr 2023]

[6] Southall NT,Lau LPL.IRDiRC Data Mining and Repurposing Task ForceThe use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.Orphanet J Rare Dis2019;14:225 PMCID:PMC6794821

[7] Begley CG,Baell J.Drug repurposing: misconceptions, challenges, and opportunities for academic researchers.Sci Transl Med2021;13:eabd5524

[8] Shim JS.Recent advances in drug repositioning for the discovery of new anticancer drugs.Int J Biol Sci2014;10:654-63 PMCID:PMC4081601

[9] Ghofrani HA,Grimminger F.Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.Nat Rev Drug Discov2006;5:689-702 PMCID:PMC7097805

[10] Jourdan JP,Rochais C.Drug repositioning: a brief overview.J Pharm Pharmacol2020;72:1145-51 PMCID:PMC7262062

[11] Barnett CF.Sildenafil in the treatment of pulmonary hypertension.Vasc Health Risk Manag2006;2:411-22 PMCID:PMC1994020

[12] Roy S,Salloum FN.Cardiac effects of phosphodiesterase-5 inhibitors: efficacy and safety.Cardiovasc Drugs Ther2021;Online ahead of print. PMCID:PMC9010479

[13] Pan Y,Wang Y.Pathway analysis for drug repositioning based on public database mining.J Chem Inf Model2014;54:407-18 PMCID:PMC3956470

[14] Pagliazzi A,Traficante G.PIK3CA-related overgrowth spectrum from diagnosis to targeted therapy: a case of CLOVES syndrome treated with Alpelisib.Front Pediatr2021;9:732836 PMCID:PMC8459713

[15] Scherman D.Drug repositioning for rare diseases: knowledge-based success stories.Therapie2020;75:161-7

[16] Chang DY,Lu YS.Role of Alpelisib in the treatment of PIK3CA-mutated breast cancer: patient selection and clinical perspectives.Ther Clin Risk Manag2021;17:193-207 PMCID:PMC7943556

[17] Madsen RR,Semple RK.Cancer-associated PIK3CA mutations in overgrowth disorders.Trends Mol Med2018;24:856-70 PMCID:PMC6185869

[18] Venot Q,Rabia SH.Targeted therapy in patients with PIK3CA-related overgrowth syndrome.Nature2018;558:540-6 PMCID:PMC7610773

[19] Canaud G,Irvine A.LBA23 EPIK-P1: retrospective chart review study of patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programme.Ann Oncol2021;32:S1297

[20] Rosenblatt M.How academia and the pharmaceutical industry can work together: the president’s lecture, annual meeting of the American Thoracic Society, San Francisco, California.Ann Am Thorac Soc2013;10:31-8

[21] den Berg S,Leufkens HGM.Drug repurposing for rare diseases: a role for academia.Front Pharmacol2021;12:746987 PMCID:PMC8564285

[22] Hernandez JJ,Smith L.Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics.Front Oncol2017;7:273 PMCID:PMC5694537

[23] Fetro C.Drug repurposing in rare diseases: myths and reality.Therapie2020;75:157-60

[24] Bharadwaj PR,Porter T.Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases.Transl Psychiatry2013;3:e332 PMCID:PMC4030329

[25] Prinz F,Asadullah K.Believe it or not: how much can we rely on published data on potential drug targets?.Nat Rev Drug Discov2011;10:712

[26] WHO-EURO. Repurposing of medicines - the underrated champion of sustainable innovation: policy brief. Available from: https://apps.who.int/iris/handle/10665/342567 [Last accessed on 7 Apr 2023]

[27] Cha Y,Reynolds IJ.Drug repurposing from the perspective of pharmaceutical companies.Br J Pharmacol2018;175:168-80 PMCID:PMC5758385

[28] Conour J. Why method of treatment patents for repurposed drugs are worth the investment. Available from: https://www.jdsupra.com/legalnews/why-method-of-treatment-patents-for-92813/ [Last accessed on 7 Apr 2023]

[29] Verbaanderd C,Huys I.Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.Trials2021;22:322 PMCID:PMC8093905

[30] Léauté-Labrèze C,Hubiche T,Thambo JB.Propranolol for severe hemangiomas of infancy.N Engl J Med2008;358:2649-51

[31] Drolet BA,Chamlin SL.Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.Pediatrics2013;131:128-40 PMCID:PMC3529954

[32] U.S. Department of Health and Human Services; Food and Drug Administration. Best practices in developing proprietary names for human prescription drug products guidance for industry. Available from: https://www.fda.gov/media/88496/download [Last accessed on 7 Apr 2023]

[33] Léauté-Labrèze C,Mazereeuw-Hautier J.A randomized, controlled trial of oral propranolol in infantile hemangioma.N Engl J Med2015;372:735-46

[34] Phillips RJ,Bekhor PS.Use of propranolol for treatment of infantile haemangiomas in an outpatient setting.J Paediatr Child Health2012;48:902-6

[35] European Medicines Agency. Paediatric-use marketing authorisations. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/paediatric-medicines/paediatric-use-marketing-authorisations [Last accessed on 7 Apr 2023]

[36] Hachem M,Diociaiuti A,Teruzzi C.Cost-utility analysis of propranolol versus corticosteroids in the treatment of proliferating infantile hemangioma in Italy.PharmacoEcon Ital Res Artic2015;17

[37] Jadeja N. The role of IP in strategies for repurposing medicines. Available from: http://www.pinsentmasons.com/out-law/analysis/the-role-of-ip-strategies-repurposing-medicines [Last accessed on 7 Apr 2023]

[38] Veldman A,Hacker C.The use of off-label medications in newborn infants despite an approved alternative being available-results of a national survey.Pharmacy (Basel)2022;10:19 PMCID:PMC8877519

[39] Ahmed F,Ali SR.Strengthening the bridge between academic and the industry through the academia-industry collaboration plan design model.Front Psychol2022;13:875940 PMCID:PMC9207471

[40] European Commission. Commission Expert Group on safe and timely access to medicines for patients (“STAMP”). Available from: https://health.ec.europa.eu/medicinal-products/pharmaceutical-committee-veterinary-pharmaceutical-committee-and-expert-groups/commission-expert-group-safe-and-timely-access-medicines-patients-stamp_en [Last accessed on 7 Apr 2023]

[41] European Medicines Agency. Proposal for a framework to support not-for-profit organisations and academia (institutions and individuals) in drug repurposing. Available from: https://www.ema.europa.eu/en/documents/other/question-answers-repurposing-pilot-project-proposal-framework-support-not-profit-organisations_en.pdf [Last accessed on 7 Apr 2023]

[42] European Medicines Agency. Building a European innovation platform for the repurposing of medicinal products. Available from: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2021-disease-04-02 [Last accessed on 7 Apr 2023]

[43] Hechtelt Jonker A,Gabaldo M.Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.Nat Rev Drug Discov2020;19:495-6

[44] Deplanque D,Ferry A.Drug repurposing: from the discovery of a useful pharmacological effect to making the treatment available to the patient.Therapie2023;78:10-8

[45] Innovative health initiative. Available from: https://www.ihi.europa.eu/about-ihi [Last accessed on 7 Apr 2023]